Review



ube2d3  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech ube2d3
    Copper metabolism related genes DLD and <t>UBE2D3</t> act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.
    Ube2d3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/UBE2D1%2F2%2F3%2F4+Antibody/pmc12968851-68-13-17
    Average 93 stars, based on 26 article reviews
    ube2d3 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma"

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    Journal: Translational Andrology and Urology

    doi: 10.21037/tau-2025-427

    Copper metabolism related genes DLD and UBE2D3 act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.
    Figure Legend Snippet: Copper metabolism related genes DLD and UBE2D3 act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.

    Techniques Used: Quantitative Proteomics, Expressing

    UBE2D3 functional analysis. (A) UBE2D3 gene expression risk prognostic model. (B) UBE2D3 protein interaction network diagram. (C) Volcano plot based on UBE2D3. (D) GO analysis of differential genes between high and low UBE2D3 groups. (E) KEGG enrichment analysis between high and low UBE2D3 groups. (F) GSEA signal pathway enrichment analysis based on UBE2D3 expression. BP, biological process; CC, cellular component; ES, Enrichment Score; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NP, nominal P value.
    Figure Legend Snippet: UBE2D3 functional analysis. (A) UBE2D3 gene expression risk prognostic model. (B) UBE2D3 protein interaction network diagram. (C) Volcano plot based on UBE2D3. (D) GO analysis of differential genes between high and low UBE2D3 groups. (E) KEGG enrichment analysis between high and low UBE2D3 groups. (F) GSEA signal pathway enrichment analysis based on UBE2D3 expression. BP, biological process; CC, cellular component; ES, Enrichment Score; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NP, nominal P value.

    Techniques Used: Functional Assay, Gene Expression, Expressing

    Correlation analysis between UBE2D3 expression and immune cells. (A) Using CIBERSORT method to explore the differences in expression levels of 22 immune cells at different levels of UBE2D3. (B) Correlation analysis between 22 different immune cells. (C) Correlation analysis between UBE2D3 expression levels and biological markers between B cell, Th cell, CD8 + T cell, and DC. (D) Correlation analysis between UBE2D3 expression levels and biological markers between M2 macrophages. (E) Correlation analysis between UBE2D3 expression levels and biological markers between CAF, MDSC, and TAM. (F) Expression of UBE2D3 Correlation analysis chart between levels and biological markers of T exhausted cell, Treg T cell, and macrophages. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. CAF, cancer-associated fibroblast; CIBERSORT, Cell-Identification By Estimating Relative Subsets Of RNA Transcripts; MDSC, myeloid-derived suppressor cells; TAM, tumor-associated macrophages.
    Figure Legend Snippet: Correlation analysis between UBE2D3 expression and immune cells. (A) Using CIBERSORT method to explore the differences in expression levels of 22 immune cells at different levels of UBE2D3. (B) Correlation analysis between 22 different immune cells. (C) Correlation analysis between UBE2D3 expression levels and biological markers between B cell, Th cell, CD8 + T cell, and DC. (D) Correlation analysis between UBE2D3 expression levels and biological markers between M2 macrophages. (E) Correlation analysis between UBE2D3 expression levels and biological markers between CAF, MDSC, and TAM. (F) Expression of UBE2D3 Correlation analysis chart between levels and biological markers of T exhausted cell, Treg T cell, and macrophages. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. CAF, cancer-associated fibroblast; CIBERSORT, Cell-Identification By Estimating Relative Subsets Of RNA Transcripts; MDSC, myeloid-derived suppressor cells; TAM, tumor-associated macrophages.

    Techniques Used: Expressing, Derivative Assay

    UBE2D3 affects the tumor immune microenvironment. (A) Using TIMER database to evaluate the correlation between UBE2D3 and immune cells. (B) Box plot shows the distribution of each immune subgroup in KIRC at each copy number state, comparing the infiltration levels of each SCNA category with normal levels. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. KIRC, kidney renal clear cell carcinoma; SCNA, Somatic Copy-number Alteration; TCGA, The Cancer Genome Atlas; TIMER, Tumor Immune Estimation Resource.
    Figure Legend Snippet: UBE2D3 affects the tumor immune microenvironment. (A) Using TIMER database to evaluate the correlation between UBE2D3 and immune cells. (B) Box plot shows the distribution of each immune subgroup in KIRC at each copy number state, comparing the infiltration levels of each SCNA category with normal levels. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. KIRC, kidney renal clear cell carcinoma; SCNA, Somatic Copy-number Alteration; TCGA, The Cancer Genome Atlas; TIMER, Tumor Immune Estimation Resource.

    Techniques Used:

    Expression and infiltration of UBE2D3 among different cell populations in the single-cell sequencing dataset. (A) The expression of UBE2D3 in different cells in different datasets. (B) The distribution of GSE139555 cells in the scRNA seq dataset. (C) The distribution of 11 annotation groups in the scRNA seq dataset. (D) The distribution of UBE2D3 in different cells in the scRNA seq dataset. (E) The expression differences of UBE2D3 in different cells between KIRC patients and normal individuals. (F) The expression differences of UBE2D3 in different tumor stages and cells. GSE, GEO Series Accession Number; KIRC, kidney renal clear cell carcinoma; N.S., not significant; NAT, normal adjacent tissue; PBMC, peripheral blood mononuclear cells; scRNA seq, single-cell RNA sequencing; TNM, tumor-node-metastasis; TPM, transcripts per million.
    Figure Legend Snippet: Expression and infiltration of UBE2D3 among different cell populations in the single-cell sequencing dataset. (A) The expression of UBE2D3 in different cells in different datasets. (B) The distribution of GSE139555 cells in the scRNA seq dataset. (C) The distribution of 11 annotation groups in the scRNA seq dataset. (D) The distribution of UBE2D3 in different cells in the scRNA seq dataset. (E) The expression differences of UBE2D3 in different cells between KIRC patients and normal individuals. (F) The expression differences of UBE2D3 in different tumor stages and cells. GSE, GEO Series Accession Number; KIRC, kidney renal clear cell carcinoma; N.S., not significant; NAT, normal adjacent tissue; PBMC, peripheral blood mononuclear cells; scRNA seq, single-cell RNA sequencing; TNM, tumor-node-metastasis; TPM, transcripts per million.

    Techniques Used: Expressing, Single Cell, Sequencing, RNA Sequencing

    UBE2D3 mutation and methylation analysis. (A) Methylation level analysis of UBE2D3 between tumor and normal groups. (B) Methylation level analysis of UBE2D3 in normal group and different stage. (C) Methylation level analysis of UBE2D3 in normal group and different grade stages. (D) Methylation level analysis of UBE2D3 in normal group and different N-stage. (E) Heat map analysis of DNA methylation in the MethSurv database. (F) Correlation between CNV and expression level of UBE2D3. (G) Correlation between CNV level of UBE2D3 and survival. *, P<0.05; **, P<0.01; ***, P<0.001. CNV, copy number variation; Cor, correlation; DFI, disease-free interval; DSS, disease-specific survival; FDR, false discovery rate; KIRC, kidney renal clear cell carcinoma; mRNA, messenger RNA; N, node; OS, overall survival; PFS, progression-free survival; RSEM, RNA-seq by expectation-maximization; TCGA, The Cancer Genome Atlas.
    Figure Legend Snippet: UBE2D3 mutation and methylation analysis. (A) Methylation level analysis of UBE2D3 between tumor and normal groups. (B) Methylation level analysis of UBE2D3 in normal group and different stage. (C) Methylation level analysis of UBE2D3 in normal group and different grade stages. (D) Methylation level analysis of UBE2D3 in normal group and different N-stage. (E) Heat map analysis of DNA methylation in the MethSurv database. (F) Correlation between CNV and expression level of UBE2D3. (G) Correlation between CNV level of UBE2D3 and survival. *, P<0.05; **, P<0.01; ***, P<0.001. CNV, copy number variation; Cor, correlation; DFI, disease-free interval; DSS, disease-specific survival; FDR, false discovery rate; KIRC, kidney renal clear cell carcinoma; mRNA, messenger RNA; N, node; OS, overall survival; PFS, progression-free survival; RSEM, RNA-seq by expectation-maximization; TCGA, The Cancer Genome Atlas.

    Techniques Used: Mutagenesis, Methylation, DNA Methylation Assay, Expressing, RNA Sequencing

    Analyze the drug sensitivity of UBE2D3 in KIRC and predict the IC 50 of the drug. (A) Vincristine. (B) Bosutinib. (C) Ambazone. (D) Finefloxacin. (E) Anagrelide. (F) Meclizine. (G) Dabrafenib. (H) Navitoclax. (I) Propranolol. ***, P<0.001. IC 50 , median inhibitory concentration; KIRC, kidney renal clear cell carcinoma.
    Figure Legend Snippet: Analyze the drug sensitivity of UBE2D3 in KIRC and predict the IC 50 of the drug. (A) Vincristine. (B) Bosutinib. (C) Ambazone. (D) Finefloxacin. (E) Anagrelide. (F) Meclizine. (G) Dabrafenib. (H) Navitoclax. (I) Propranolol. ***, P<0.001. IC 50 , median inhibitory concentration; KIRC, kidney renal clear cell carcinoma.

    Techniques Used: Concentration Assay

    Molecular docking patterns of key drugs and core targets. (A) Vincristine binding to P113 isosite. (B) Bosutinib binding to S100 isosite. (C) Ambazone binding to L89 isosite. (D) Finefloxacin binding to P95 isosite. (E) Anagrelide binding to T98 isosite. (F) Meclizine binding to P57 isosite. (G) Dabrafenib binding to K63 isosite. (H) Navitoclax binding to A68 isosite. (I) Propanol binding to E9 isosite. (J) Different small molecule drugs binding to target UBE2D3 Vina score comparison.
    Figure Legend Snippet: Molecular docking patterns of key drugs and core targets. (A) Vincristine binding to P113 isosite. (B) Bosutinib binding to S100 isosite. (C) Ambazone binding to L89 isosite. (D) Finefloxacin binding to P95 isosite. (E) Anagrelide binding to T98 isosite. (F) Meclizine binding to P57 isosite. (G) Dabrafenib binding to K63 isosite. (H) Navitoclax binding to A68 isosite. (I) Propanol binding to E9 isosite. (J) Different small molecule drugs binding to target UBE2D3 Vina score comparison.

    Techniques Used: Binding Assay, Comparison

    Immunostaining image of UBE2D3 . (A) Expression of UBE2D3 in Para cancer (100×). (B) Expression of UBE2D3 in Para cancer (200×). (C) Expression of UBE2D3 in KIRC (100×). (D) Expression of UBE2D3 in KIRC (200×). (E) IHC staining statistics of UBE2D3 in KIRC and adjacent tissues. **, P<0.01. AOD, average optical density; IHC, immunohistochemistry; KIRC, kidney renal clear cell carcinoma.
    Figure Legend Snippet: Immunostaining image of UBE2D3 . (A) Expression of UBE2D3 in Para cancer (100×). (B) Expression of UBE2D3 in Para cancer (200×). (C) Expression of UBE2D3 in KIRC (100×). (D) Expression of UBE2D3 in KIRC (200×). (E) IHC staining statistics of UBE2D3 in KIRC and adjacent tissues. **, P<0.01. AOD, average optical density; IHC, immunohistochemistry; KIRC, kidney renal clear cell carcinoma.

    Techniques Used: Immunostaining, Expressing, Immunohistochemistry

    Related Articles

    Incubation:

    Article Title: Prognostic value and immunological function of cuproptosis-related genes in lung adenocarcinoma
    Article Snippet: .. LUAD and paracancerous tissue samples were collected, and 3 mm of tumor sections were incubated with commercial rabbit polyclonal antibodies against COA6 (24209-1-AP, Proteintech), UBE2D1 (DF6715, Affinity), DLAT (13426-1-AP, Proteintech), SLC25A3 (10420-1-AP, Proteintech), DBH (DF7060, Affinity), LOXL2 (DF13442, Affinity) at 1/100 dilution overnight at 4 o C. Then, the sections were conjugated with horseradish peroxidase antibody at room temperature for 2 h, then substrates of the Envision system-HRP from the kit were added to incubate with stained slices as the manufacturer's protocol described. .. The signals were analyzed with a light microscope (Olympus 600, Tokyo, Japan).

    Article Title: DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation
    Article Snippet: HA-ub-K48 or HA-ub-K63 protein were purified from 293T cells by immobilization with anti-HA magnetic beads (MCE, HY-K0201) and eluted with HA peptides (MCE, HY-P0239) in TBS buffer. .. The DDX39B ubiquitylation reaction mixture was composed of 150 μM HA-ub-K48 or HA-ub-K63, 150 nM UBE1 (Proteintech, Ag8920), 300 nM UBE2D1 (Proteintech, Ag1932), 350 nM His-TRIM28 or His-TRIM28-C65A, and 4 μM GST-DDX39B in a reaction buffer (50 mM Tris-HCl (pH = 7.5), 2 mM ATP, 50 mM NaCl, 5 mM MgCl 2 , 1 mM DTT) and incubated at 37 °C for 1 h. The reactions were stopped by adding an equal volume of 2× loading buffer and boiling for 10 min, followed by Western blotting. ..

    Article Title: DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation.
    Article Snippet: In vitro ubiquitination assay HA-ub-K48 or HA-ub-K63 protein were purified from 293T cells by immobilization with anti-HA magnetic beads (MCE, HY-K0201) and eluted with HA peptides (MCE, HY-P0239) in TBS buffer. .. The DDX39B ubiquitylation reaction mixture was composed of 150 μM HA-ub-K48 or HA-ub-K63, 150 nM UBE1 (Proteintech, Ag8920), 300 nM UBE2D1 (Proteintech, Ag1932), 350 nM His-TRIM28 or HisTRIM28-C65A, and 4 μM GST-DDX39B in a reaction buffer (50 mM Tris-HCl (pH= 7.5), 2 mM ATP, 50mM NaCl, 5 mM MgCl2, 1 mM DTT) and incubated at 37 °C for 1 h. The reactions were stopped by adding an equal volume of 2× loading buffer and boiling for 10min, followed by Western blotting. ..

    Article Title: Prognostic value and immunological function of cuproptosis-related genes in lung adenocarcinoma
    Article Snippet: .. Immunohistochemistry (IHC) LUAD and paracancerous tissue samples were collected, and three millimeters of tumor sections were incubated with commercial rabbit polyclonal antibodies against COA6 (24209-1-AP, Proteintech), UBE2D1 (DF6715, A nity), DLAT (13426-1-AP, Proteintech), SLC25A3 (10420-1-AP, Proteintech), DBH (DF7060, A nity), LOXL2 (DF13442, A nity) at 1/100 dilution overnight at 4oC. ..

    Staining:

    Article Title: Prognostic value and immunological function of cuproptosis-related genes in lung adenocarcinoma
    Article Snippet: .. LUAD and paracancerous tissue samples were collected, and 3 mm of tumor sections were incubated with commercial rabbit polyclonal antibodies against COA6 (24209-1-AP, Proteintech), UBE2D1 (DF6715, Affinity), DLAT (13426-1-AP, Proteintech), SLC25A3 (10420-1-AP, Proteintech), DBH (DF7060, Affinity), LOXL2 (DF13442, Affinity) at 1/100 dilution overnight at 4 o C. Then, the sections were conjugated with horseradish peroxidase antibody at room temperature for 2 h, then substrates of the Envision system-HRP from the kit were added to incubate with stained slices as the manufacturer's protocol described. .. The signals were analyzed with a light microscope (Olympus 600, Tokyo, Japan).

    Western Blot:

    Article Title: DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation
    Article Snippet: HA-ub-K48 or HA-ub-K63 protein were purified from 293T cells by immobilization with anti-HA magnetic beads (MCE, HY-K0201) and eluted with HA peptides (MCE, HY-P0239) in TBS buffer. .. The DDX39B ubiquitylation reaction mixture was composed of 150 μM HA-ub-K48 or HA-ub-K63, 150 nM UBE1 (Proteintech, Ag8920), 300 nM UBE2D1 (Proteintech, Ag1932), 350 nM His-TRIM28 or His-TRIM28-C65A, and 4 μM GST-DDX39B in a reaction buffer (50 mM Tris-HCl (pH = 7.5), 2 mM ATP, 50 mM NaCl, 5 mM MgCl 2 , 1 mM DTT) and incubated at 37 °C for 1 h. The reactions were stopped by adding an equal volume of 2× loading buffer and boiling for 10 min, followed by Western blotting. ..

    Article Title: DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation.
    Article Snippet: In vitro ubiquitination assay HA-ub-K48 or HA-ub-K63 protein were purified from 293T cells by immobilization with anti-HA magnetic beads (MCE, HY-K0201) and eluted with HA peptides (MCE, HY-P0239) in TBS buffer. .. The DDX39B ubiquitylation reaction mixture was composed of 150 μM HA-ub-K48 or HA-ub-K63, 150 nM UBE1 (Proteintech, Ag8920), 300 nM UBE2D1 (Proteintech, Ag1932), 350 nM His-TRIM28 or HisTRIM28-C65A, and 4 μM GST-DDX39B in a reaction buffer (50 mM Tris-HCl (pH= 7.5), 2 mM ATP, 50mM NaCl, 5 mM MgCl2, 1 mM DTT) and incubated at 37 °C for 1 h. The reactions were stopped by adding an equal volume of 2× loading buffer and boiling for 10min, followed by Western blotting. ..

    other:

    Article Title: The E3 ubiquitin ligase FBXL18 stabilizes BST2 to promote inflammation in RABV-infected astrocytes
    Article Snippet: The antibodies against Phospho-NF-κB (CST, cat#3033), Phospho-IKKα/β (CST, cat#2697), PCNA (CST, cat#13110), GAPDH (CST, cat#2118), NF-κB (CST, cat#8242), IκBα (Beyotime Biotechnology, cat#AF1282), HA (Beyotime Biotechnology, cat#AF2858), β-actin (Beyotime Biotechnology, cat#AF2815), BST2 (mouse, Abcam, cat#ab272169), BST2 (human, Abcam, cat#ab243229), FBXL18 (Bioss, cat#bs-16039R; and was validated using IB/IP in Fig. ), GFAP (Abcam, cat#ab279291), NeuN (Abcam, cat#ab177487), UBE2D1 (proteintech, cat#15475-1-SP), ASB2 (ABclonal, cat#A17923), WWP1 (proteintech, cat#6704-1-Ig), Hrd1 (ABclonal, cat#A2605), FBXL22(abcam, cat#223059), NEDD4 (Proteintech, cat#21698-1-SP), Flag (Proteintech, cat#66008-4-Ig), NP Antibody (Sino Biological, cat#11675-T62), Alexa Fluor 594 goat anti-chicken antibody (Thermo, cat#A32759), horseradish peroxidase (HRP)-labeled IgG mouse secondary antibodies (Beyotime Biotechnology, cat#A0216) and rabbit secondary antibodies (Beyotime Biotechnology, cat#A0208) were obtained.

    Immunohistochemistry:

    Article Title: Prognostic value and immunological function of cuproptosis-related genes in lung adenocarcinoma
    Article Snippet: .. Immunohistochemistry (IHC) LUAD and paracancerous tissue samples were collected, and three millimeters of tumor sections were incubated with commercial rabbit polyclonal antibodies against COA6 (24209-1-AP, Proteintech), UBE2D1 (DF6715, A nity), DLAT (13426-1-AP, Proteintech), SLC25A3 (10420-1-AP, Proteintech), DBH (DF7060, A nity), LOXL2 (DF13442, A nity) at 1/100 dilution overnight at 4oC. ..



    Similar Products

    gst ube2d1  (TargetMol)
    94
    TargetMol gst ube2d1
    Gst Ube2d1, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/UBE2D1+Protein%2C+Human%2C+Recombinant/pm41507172-435-39-41
    Average 94 stars, based on 1 article reviews
    gst ube2d1 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ubch5a e2  (R&D Systems)
    95
    R&D Systems ubch5a e2
    Ubch5a E2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/Recombinant+Human+UbcH5a%2FUBE2D1+Protein%2C+CF/us12590953-830-6-15
    Average 95 stars, based on 1 article reviews
    ubch5a e2 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    e2 e2 616 r d systems  (R&D Systems)
    95
    R&D Systems e2 e2 616 r d systems
    E2 E2 616 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/Recombinant+Human+UbcH5a%2FUBE2D1+Protein%2C+CF/pm41857001-159-28-30
    Average 95 stars, based on 1 article reviews
    e2 e2 616 r d systems - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    e 306 050 ube2d1 r d systems cat  (R&D Systems)
    94
    R&D Systems e 306 050 ube2d1 r d systems cat
    E 306 050 Ube2d1 R D Systems Cat, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/Recombinant+Human+GST-Ubiquitin+E1+Enzyme+(UBE1)+Protein%2C+CF/pm41780531-217-160-162
    Average 94 stars, based on 1 article reviews
    e 306 050 ube2d1 r d systems cat - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ha ubiquitin r d systems cat  (R&D Systems)
    95
    R&D Systems ha ubiquitin r d systems cat
    Ha Ubiquitin R D Systems Cat, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/Recombinant+Human+UbcH5a%2FUBE2D1+Protein%2C+CF/pm41780531-217-166-167
    Average 95 stars, based on 1 article reviews
    ha ubiquitin r d systems cat - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    ube2d3  (Proteintech)
    93
    Proteintech ube2d3
    Copper metabolism related genes DLD and <t>UBE2D3</t> act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.
    Ube2d3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/UBE2D1%2F2%2F3%2F4+Antibody/pmc12968851-68-13-17
    Average 93 stars, based on 1 article reviews
    ube2d3 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    tissue sections  (Proteintech)
    93
    Proteintech tissue sections
    Copper metabolism related genes DLD and <t>UBE2D3</t> act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.
    Tissue Sections, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/UBE2D1%2F2%2F3%2F4+Antibody/pmc12968851-68-2-17
    Average 93 stars, based on 1 article reviews
    tissue sections - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ube2d1  (Proteintech)
    93
    Proteintech ube2d1
    Copper metabolism related genes DLD and <t>UBE2D3</t> act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.
    Ube2d1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ube2d1/UBE2D1%2F2%2F3%2F4+Antibody/pm41390767-232-57-58
    Average 93 stars, based on 1 article reviews
    ube2d1 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Copper metabolism related genes DLD and UBE2D3 act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: Copper metabolism related genes DLD and UBE2D3 act as protective factors in KIRC. (A) The OS Kaplan-Meier curve of DLD genes. (B) The ROC curve of DLD gene. (C) The Kaplan-Meier curve (OS) of UBE2D3 gene. The ROC curve of UBE2D3 gene (D) shows the differential expression of UBE2D3 gene at different T stages (E). (F) The expression differences of gene UBE2D3 in different G stages. (G) The calibration curve of the Norman plot is used to predict 1-, 3-, and 5-year survival rates. (H) By drawing a line graph, we predicted the OS period over a time range of 1-, 3-, and 5-year. Each risk factor corresponds to a point axis by drawing a line on the graph. *, P<0.05; **, P<0.01; ***, P<0.001. AUC, area under the curve; CI, confidence interval; G, grade; H, high; HR, hazard ratio; KIRC, kidney renal clear cell carcinoma; L, low; OS, overall survival; ROC, receiver operating characteristic; T, tumor.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Quantitative Proteomics, Expressing

    UBE2D3 functional analysis. (A) UBE2D3 gene expression risk prognostic model. (B) UBE2D3 protein interaction network diagram. (C) Volcano plot based on UBE2D3. (D) GO analysis of differential genes between high and low UBE2D3 groups. (E) KEGG enrichment analysis between high and low UBE2D3 groups. (F) GSEA signal pathway enrichment analysis based on UBE2D3 expression. BP, biological process; CC, cellular component; ES, Enrichment Score; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NP, nominal P value.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: UBE2D3 functional analysis. (A) UBE2D3 gene expression risk prognostic model. (B) UBE2D3 protein interaction network diagram. (C) Volcano plot based on UBE2D3. (D) GO analysis of differential genes between high and low UBE2D3 groups. (E) KEGG enrichment analysis between high and low UBE2D3 groups. (F) GSEA signal pathway enrichment analysis based on UBE2D3 expression. BP, biological process; CC, cellular component; ES, Enrichment Score; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NP, nominal P value.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Functional Assay, Gene Expression, Expressing

    Correlation analysis between UBE2D3 expression and immune cells. (A) Using CIBERSORT method to explore the differences in expression levels of 22 immune cells at different levels of UBE2D3. (B) Correlation analysis between 22 different immune cells. (C) Correlation analysis between UBE2D3 expression levels and biological markers between B cell, Th cell, CD8 + T cell, and DC. (D) Correlation analysis between UBE2D3 expression levels and biological markers between M2 macrophages. (E) Correlation analysis between UBE2D3 expression levels and biological markers between CAF, MDSC, and TAM. (F) Expression of UBE2D3 Correlation analysis chart between levels and biological markers of T exhausted cell, Treg T cell, and macrophages. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. CAF, cancer-associated fibroblast; CIBERSORT, Cell-Identification By Estimating Relative Subsets Of RNA Transcripts; MDSC, myeloid-derived suppressor cells; TAM, tumor-associated macrophages.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: Correlation analysis between UBE2D3 expression and immune cells. (A) Using CIBERSORT method to explore the differences in expression levels of 22 immune cells at different levels of UBE2D3. (B) Correlation analysis between 22 different immune cells. (C) Correlation analysis between UBE2D3 expression levels and biological markers between B cell, Th cell, CD8 + T cell, and DC. (D) Correlation analysis between UBE2D3 expression levels and biological markers between M2 macrophages. (E) Correlation analysis between UBE2D3 expression levels and biological markers between CAF, MDSC, and TAM. (F) Expression of UBE2D3 Correlation analysis chart between levels and biological markers of T exhausted cell, Treg T cell, and macrophages. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. CAF, cancer-associated fibroblast; CIBERSORT, Cell-Identification By Estimating Relative Subsets Of RNA Transcripts; MDSC, myeloid-derived suppressor cells; TAM, tumor-associated macrophages.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Expressing, Derivative Assay

    UBE2D3 affects the tumor immune microenvironment. (A) Using TIMER database to evaluate the correlation between UBE2D3 and immune cells. (B) Box plot shows the distribution of each immune subgroup in KIRC at each copy number state, comparing the infiltration levels of each SCNA category with normal levels. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. KIRC, kidney renal clear cell carcinoma; SCNA, Somatic Copy-number Alteration; TCGA, The Cancer Genome Atlas; TIMER, Tumor Immune Estimation Resource.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: UBE2D3 affects the tumor immune microenvironment. (A) Using TIMER database to evaluate the correlation between UBE2D3 and immune cells. (B) Box plot shows the distribution of each immune subgroup in KIRC at each copy number state, comparing the infiltration levels of each SCNA category with normal levels. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. KIRC, kidney renal clear cell carcinoma; SCNA, Somatic Copy-number Alteration; TCGA, The Cancer Genome Atlas; TIMER, Tumor Immune Estimation Resource.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques:

    Expression and infiltration of UBE2D3 among different cell populations in the single-cell sequencing dataset. (A) The expression of UBE2D3 in different cells in different datasets. (B) The distribution of GSE139555 cells in the scRNA seq dataset. (C) The distribution of 11 annotation groups in the scRNA seq dataset. (D) The distribution of UBE2D3 in different cells in the scRNA seq dataset. (E) The expression differences of UBE2D3 in different cells between KIRC patients and normal individuals. (F) The expression differences of UBE2D3 in different tumor stages and cells. GSE, GEO Series Accession Number; KIRC, kidney renal clear cell carcinoma; N.S., not significant; NAT, normal adjacent tissue; PBMC, peripheral blood mononuclear cells; scRNA seq, single-cell RNA sequencing; TNM, tumor-node-metastasis; TPM, transcripts per million.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: Expression and infiltration of UBE2D3 among different cell populations in the single-cell sequencing dataset. (A) The expression of UBE2D3 in different cells in different datasets. (B) The distribution of GSE139555 cells in the scRNA seq dataset. (C) The distribution of 11 annotation groups in the scRNA seq dataset. (D) The distribution of UBE2D3 in different cells in the scRNA seq dataset. (E) The expression differences of UBE2D3 in different cells between KIRC patients and normal individuals. (F) The expression differences of UBE2D3 in different tumor stages and cells. GSE, GEO Series Accession Number; KIRC, kidney renal clear cell carcinoma; N.S., not significant; NAT, normal adjacent tissue; PBMC, peripheral blood mononuclear cells; scRNA seq, single-cell RNA sequencing; TNM, tumor-node-metastasis; TPM, transcripts per million.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Expressing, Single Cell, Sequencing, RNA Sequencing

    UBE2D3 mutation and methylation analysis. (A) Methylation level analysis of UBE2D3 between tumor and normal groups. (B) Methylation level analysis of UBE2D3 in normal group and different stage. (C) Methylation level analysis of UBE2D3 in normal group and different grade stages. (D) Methylation level analysis of UBE2D3 in normal group and different N-stage. (E) Heat map analysis of DNA methylation in the MethSurv database. (F) Correlation between CNV and expression level of UBE2D3. (G) Correlation between CNV level of UBE2D3 and survival. *, P<0.05; **, P<0.01; ***, P<0.001. CNV, copy number variation; Cor, correlation; DFI, disease-free interval; DSS, disease-specific survival; FDR, false discovery rate; KIRC, kidney renal clear cell carcinoma; mRNA, messenger RNA; N, node; OS, overall survival; PFS, progression-free survival; RSEM, RNA-seq by expectation-maximization; TCGA, The Cancer Genome Atlas.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: UBE2D3 mutation and methylation analysis. (A) Methylation level analysis of UBE2D3 between tumor and normal groups. (B) Methylation level analysis of UBE2D3 in normal group and different stage. (C) Methylation level analysis of UBE2D3 in normal group and different grade stages. (D) Methylation level analysis of UBE2D3 in normal group and different N-stage. (E) Heat map analysis of DNA methylation in the MethSurv database. (F) Correlation between CNV and expression level of UBE2D3. (G) Correlation between CNV level of UBE2D3 and survival. *, P<0.05; **, P<0.01; ***, P<0.001. CNV, copy number variation; Cor, correlation; DFI, disease-free interval; DSS, disease-specific survival; FDR, false discovery rate; KIRC, kidney renal clear cell carcinoma; mRNA, messenger RNA; N, node; OS, overall survival; PFS, progression-free survival; RSEM, RNA-seq by expectation-maximization; TCGA, The Cancer Genome Atlas.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Mutagenesis, Methylation, DNA Methylation Assay, Expressing, RNA Sequencing

    Analyze the drug sensitivity of UBE2D3 in KIRC and predict the IC 50 of the drug. (A) Vincristine. (B) Bosutinib. (C) Ambazone. (D) Finefloxacin. (E) Anagrelide. (F) Meclizine. (G) Dabrafenib. (H) Navitoclax. (I) Propranolol. ***, P<0.001. IC 50 , median inhibitory concentration; KIRC, kidney renal clear cell carcinoma.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: Analyze the drug sensitivity of UBE2D3 in KIRC and predict the IC 50 of the drug. (A) Vincristine. (B) Bosutinib. (C) Ambazone. (D) Finefloxacin. (E) Anagrelide. (F) Meclizine. (G) Dabrafenib. (H) Navitoclax. (I) Propranolol. ***, P<0.001. IC 50 , median inhibitory concentration; KIRC, kidney renal clear cell carcinoma.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Concentration Assay

    Molecular docking patterns of key drugs and core targets. (A) Vincristine binding to P113 isosite. (B) Bosutinib binding to S100 isosite. (C) Ambazone binding to L89 isosite. (D) Finefloxacin binding to P95 isosite. (E) Anagrelide binding to T98 isosite. (F) Meclizine binding to P57 isosite. (G) Dabrafenib binding to K63 isosite. (H) Navitoclax binding to A68 isosite. (I) Propanol binding to E9 isosite. (J) Different small molecule drugs binding to target UBE2D3 Vina score comparison.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: Molecular docking patterns of key drugs and core targets. (A) Vincristine binding to P113 isosite. (B) Bosutinib binding to S100 isosite. (C) Ambazone binding to L89 isosite. (D) Finefloxacin binding to P95 isosite. (E) Anagrelide binding to T98 isosite. (F) Meclizine binding to P57 isosite. (G) Dabrafenib binding to K63 isosite. (H) Navitoclax binding to A68 isosite. (I) Propanol binding to E9 isosite. (J) Different small molecule drugs binding to target UBE2D3 Vina score comparison.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Binding Assay, Comparison

    Immunostaining image of UBE2D3 . (A) Expression of UBE2D3 in Para cancer (100×). (B) Expression of UBE2D3 in Para cancer (200×). (C) Expression of UBE2D3 in KIRC (100×). (D) Expression of UBE2D3 in KIRC (200×). (E) IHC staining statistics of UBE2D3 in KIRC and adjacent tissues. **, P<0.01. AOD, average optical density; IHC, immunohistochemistry; KIRC, kidney renal clear cell carcinoma.

    Journal: Translational Andrology and Urology

    Article Title: Systematic analysis of UBE2D3 and its association with prognosis, tumor microenvironment, and drug sensitivity in renal clear cell carcinoma

    doi: 10.21037/tau-2025-427

    Figure Lengend Snippet: Immunostaining image of UBE2D3 . (A) Expression of UBE2D3 in Para cancer (100×). (B) Expression of UBE2D3 in Para cancer (200×). (C) Expression of UBE2D3 in KIRC (100×). (D) Expression of UBE2D3 in KIRC (200×). (E) IHC staining statistics of UBE2D3 in KIRC and adjacent tissues. **, P<0.01. AOD, average optical density; IHC, immunohistochemistry; KIRC, kidney renal clear cell carcinoma.

    Article Snippet: The paraffin-embedded tissue sections were deparaffinized overnight at 4 °C with rabbit anti UBE2D3 (15475-1-AP, Protein, (15475-1-AP, Proteintech, Wuhan, China) at a dilution ratio of 1:400.

    Techniques: Immunostaining, Expressing, Immunohistochemistry